Shares of CRISPR Therapeutics CRSP have lost more than 30% in the past year. Though the stock soared at the onset of 2024, ...
Since two groundbreaking treatments were approved in late 2023, only a handful of patients have been able to access the ...
The "CRISPR-based Gene Editing Market by Product & Service, by Application, by End-User, and By Region" report has been added ...
CRISPR is a powerful gene-editing tool that holds enormous potential for treating genetic diseases by allowing scientists to ...
A look at Intellia Therapeutics, Inc. and Editas Medicine, Inc., including their restructuring and pipeline prioritization.
Treatments for rare diseases are hard to create and expensive to deliver, but there is new hope for editing the software of ...
ECRC researchers developed a CRISPR-based gene therapy targeting dysferlin mutations in muscular dystrophy. By editing and ...
The three-year partnership is another example of Vertex’s interest in improving on Casgevy, its CRISPR medicine for sickle ...
Researchers at the Experimental and Clinical Research Center in Berlin are developing a targeted treatment for muscular ...
It feels fantastic,” said Blau, who thanked her lab members and colleagues for their support and dedication. “This ...
Ongoing launch of CASGEVY® continues to gain momentum--2025 is poised to be a catalyst-rich year with key updates across several ...
The science has proven that gene therapies are effective treatments, and they have given hope to patients and their families ...